DIM as a Treatment for Thyroid Disease

Перакладаць артыкулы могуць толькі зарэгістраваныя карыстальнікі

Увайсці / Зарэгістравацца

Спасылка захоўваецца ў буферы абмену

СтатусПрыпынена

Спонсары

The New York Eye & Ear Infirmary

КЛІНІЧНАЕ ВЫПРАБАВАННЕ: NCT01846364

BioSeek: nct01846364

Ключавыя словы

Рэферат

Diindolylmethane (DIM), a dietary supplement, found naturally in cruciferous vegetables (such as cabbage, cauliflower, broccoli, & Brussels sprouts) has been studied extensively in recent years for its anti-cancer effects. DIM has been shown to exert control over cancer cell growth in breast, uterine, cervical, ovarian, and colon cancer.

To date no human study has been published regarding the bioavailability of DIM in thyroid tissue or its effects in proliferative thyroid disease. Our previous study attempted to elucidate DIM's promotion of anti-proliferative estrogen metabolites in proliferative thyroid disease and ascertain its uptake in thyroid tissue. DIM has been shown to concentrate in the thyroid gland. Furthermore, thyroid volumes have been seen to decrease subjectively.

This study would continue our attempt to elucidate DIM's promotion of anti-proliferative estrogen metabolites in proliferative thyroid disease.

Даты

Апошняя праверка:	03/31/2013
Упершыню прадстаўлена:	04/29/2013
Меркаваная колькасць заявак прадстаўлена:	04/29/2013
Першае паведамленне:	05/02/2013
Апошняе абнаўленне адпраўлена:	04/29/2013
Апошняе абнаўленне апублікавана:	05/02/2013
Фактычная дата пачатку даследавання:	10/31/2006
Разліковая дата першаснага завяршэння:	07/31/2011
Разліковая дата завяршэння даследавання:	08/31/2011

Стан альбо хвароба

Proliferative Thyroid Disease

Ўмяшанне / лячэнне

Dietary Supplement: A

Фаза

Групы ўзбраенняў

Рука	Ўмяшанне / лячэнне
Experimental: A Subjects with proliferative thyroid disease	Dietary Supplement: A 300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days

Крытэрыі прыдатнасці

Узрост, які мае права на вучобу	18 Years Каб 18 Years
Пол, прыдатны для навучання	All
Прымае здаровых валанцёраў	Так
Крытэрыі	Inclusion Criteria: - Adults diagnosed with abnormalities of the thyroid gland suspicious for benign adenoma, or goiterous changes. Exclusion Criteria: - Patients who are pregnant, attempting to conceive, or lactating will be excluded due to possible deleterious effects of treatment on fetus/infant. Patients taking oral contraceptives, estrogen therapy, tamoxifin or those with a history of breast cancer will be excluded. Patients with liver disease and those taking statins for hypercholesterolemia will also be excluded to decrease the potential for possible liver toxicity. Any patient with elevated liver enzymes on pretreatment blood screening will be excluded from study participation. Patients with serious systemic diseases such as renal failure, diabetes, blood dyscrasia, coagulopathy, and non-optimized cardiopulmonary disease will be excluded due to the possibility of confounding blood tests screening for toxicity.

Вынік

Першасныя вынікі

1. Evidence of objective and quantifiable changes in thyroid size as a resalt of the oral administration of DIM, confirmed by pre- and post- DIM treatment ultrasounds [after 30 days of DIM consumption and 2 and 4 weeks after DIM consumption stopped]

Меры другаснага выніку

1. Evidence of DIM's effect on estrogen metabolites, confirmed by plasma and urine analysis [after 30 days of DIM consumption]

DIM as a Treatment for Thyroid Disease

Ключавыя словы

злаякасная пухліна

diindolylmethane

капуста

капуста агародная

супрацьракавы